EIT Health Start-up Amplifier program wraps up with strong commitment to innovation in epilepsy

The EIT Health Start-up Amplifier program, which aims to promote innovative solutions to improve quality of life for people with epilepsy, brought its three-year run to a close with a final event held at the DKV headquarters in Barcelona. The initiative’s main application case was development and validation of the mjn-SERAS device and it was promoted by a consortium led by mjn-neuro with Biocat, IESE Business School, Integralia DKV Foundation, DKV, Clínica Universidad de Navarra, Oxford Health NHS Foundation Trust, Medtronic, Medical Valley, Kork, Synaptia and other international partners.

Specifically, Biocat played a key role as a promoter, coordinator and facilitator of collaboration among the various European partners, as well as in supporting and accelerating mjn-neuro in the development, validation and internationalization of the device.

The main goal of this project, co-funded by EIT Health, was to conduct a clinical trial to validate the impact of the mjn-SERAS medical device to detect epileptic seizures early in real life conditions, as well as supporting its development and market launch. This solution combined machine learning technologies, customized sensors and a mobile app that sends users early alerts that improve autonomy and safety.

Interim results obtained in June 2024 showed a 23-point improvement in patients’ quality of life, represnting a 195% increase, mainly due to a 63% to 80% drop in accidents associated with epileptic seizures. This clinical evidence was instrumental in advancing toward the commercialization of the technology.

Over the three years of the program, the consortium also implemented multiple communication, training, and co-creation activities with patient communities, healthcare professionals and social organizations. Some of the most noteworthy milestones include:

• More than 6,000 people with disabilities benefited through programs run by the Integralia DKV Foundation.
• A network working actively with epilepsy patient associations and neurology professionals to validate and enhance the device.
• Specialized training for healthcare professionals (general practitioners, pediatricians, neurologists and psychologists) to provide personalized digital services via DKV’s QC+ platform.
• Taking part in conferences like the Spanish Epilepsy Society Congress (Madrid, October 2024), where the mjn-SERAS solution was presented alongside Medtronic devices.
   

Now that the program and clinical trials are finished, the project’s promoters plan to continue their commitment to digital health and medical innovation. The final meeting, held in December 2024, served as an opportunity to recognize partners and participants and marked the beginning of a new stage for mjn-SERAS on its path to commercialization.